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Abstract
Somatostatin-14 [somatotropin release-inhibiting factor (SRIF)] reduces hippocampal epileptiform activity but the contribution of its
specific receptors (sst1)5) is poorly understood. We have focused on the role of sst1 and sst2 in mediating SRIF modulation of
epilepsy using hippocampal slices of wild-type (WT) and sst1 or sst2 knockout (KO) mice. Recordings of epileptiform discharge
induced by Mg2+-free medium with 4-aminopyridine were performed from the CA3 region before and after the application of SRIF
compounds. In WT mice, SRIF and the sst1 agonist CH-275 reduce epilepsy whereas sst1 blockade with its antagonist SRA-880
increases the bursting discharge. Activation of sst2 does not affect the bursting frequency unless its agonist octreotide is applied with
SRA-880, indicating that sst1 masks sst2-mediated modulation of epilepsy. In sst1 KO mice: (i) the bursting frequency is lower than in
WT; (ii) SRIF, CH-275 and SRA-880 are ineffective on epilepsy and (iii) octreotide is also devoid of effects, whereas blockade of sst2
with the antagonist d-Tyr8 Cyn 154806 increases the bursting frequency. In sst2 KO mice, the SRIF ligand effects are similar to those
in WT. In the whole hippocampus of sst1 KO mice, sst2 mRNA, protein and binding are higher than in WT and reverse transcription-
polymerase chain reaction of the CA3 subarea confirms an increase of the sst2 messenger. We conclude that sst1 mediates inhibitory
actions of SRIF and that interactions between sst1 and sst2 may prevent sst2 modulation of epilepsy. We suggest that, in sst1 KO
mice, activation of over-expressed sst2 reduces the bursting frequency, indicating that sst2 density represents the rate-limiting factor
for sst2-mediated modulation of epilepsy.
Introduction
Somatostatin-14 [somatotropin release-inhibiting factor (SRIF)] is a
neuropeptide widely distributed in different brain regions, including
the hippocampal formation (Binaschi et al., 2003). SRIF actions are
mediated by five receptor subtypes (sst1)5). In the rodent brain,
receptor binding studies and immunological analysis have shown a
widespread but selective distribution of distinct SRIF receptors
(Schulz et al., 2000; Weckbecker et al., 2003). SRIF receptors are
coupled to G proteins and trigger multiple transmembrane signalling
systems (Lahlou et al., 2004) mediating different functions of SRIF
receptors which also depend on their possible interactions. For
example, in recombinant systems, sst2 ⁄ 3 and sst1 ⁄ 5 receptor interac-
tions have been demonstrated (Rocheville et al., 2000; Pfeiffer et al.,
2001). However, little is known about native systems. In particular,
functional interactions have been suggested between sst2 and sst5
receptors in rat tumour somatotrophs (Cervia et al., 2003c). In
addition, sst2 and sst4 receptors appear to be functionally coupled in
the mouse hippocampus (Moneta et al., 2002). Finally, interactions
between sst1 and sst2 receptors have recently been suggested in the
mouse retina (Pavan et al., 2004).
At the neuronal level, SRIF is involved in multiple functions,
including control of excitatory neurotransmission. In the rat hippo-
campus, SRIF inhibits neuronal excitability by affecting Ca2+ and K+
conductances (Boehm & Betz, 1997; Schweitzer et al., 1998; Baraban
& Tallent, 2004). In addition, there is evidence indicating that SRIF,
possibly released by SRIF-containing interneurones participating in
the lateral inhibitory circuits in the dentate gyrus (Buckmaster et al.,
2002; Kobayashi & Buckmaster, 2003), reduces epileptiform activity
in both CA1 and CA3 hippocampal regions (Tallent & Siggins, 1997,
1999; Vezzani & Hoyer, 1999; Baraban & Tallent, 2004). These
observations suggest that SRIF plays a role in seizure control and
therefore that it may have an importance as a potential therapeutic
agent for temporal lobe epilepsy (Vezzani & Hoyer, 1999; Binaschi
et al., 2003).
Information on the precise contribution of each SRIF receptor
subtype on the SRIF-induced inhibition of epileptiform activity is still
limited. Of the five SRIF receptors, the sst2 receptor is the candidate
likely to mediate the anticonvulsant effects of SRIF in the hippocam-
pus and entorhinal cortex of rats (Vezzani & Hoyer, 1999). Previous
findings, however, have demonstrated that, in mice, these receptors do
not mediate inhibitory effects of SRIF on seizure susceptibility and
hippocampal excitatory neurotransmission. Rather, excitatory actions
of sst4 receptors have been reported (Moneta et al., 2002).
No information is available on the sst1 receptor function in
hippocampal physiology. In the rodent hippocampus, for instance, the
expression of sst1 receptors has not been conclusively demonstrated
using either immunohistochemistry or radioligand binding (Hervieu &
Emson, 1998; Schulz et al., 2000;Videau et al., 2003), whereas previous
studies have suggested that hippocampal neurones may express sst1
receptor mRNA (Perez et al., 1994; Hannon et al., 2002b).
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